Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma to Report Financial Results for the Third Quarter of
Fiscal 2012 on April 30, 2012

BOULDER, Colo., Apr 23, 2012 (BUSINESS WIRE) --Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the third quarter of fiscal 2012 on Monday, April 30, 2012, and will hold a conference call on Tuesday, May 1, 2012 at 9:00 a.m. Eastern time to discuss these results. Michael Carruthers, Chief Financial Officer, and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.

Conference Call Information


Tuesday, May 1, 2012


9:00 a.m. Eastern time


800 901.5217


617 786.2964

Pass Code:


Webcast & Conference Call Slides:

A replay of the call will be available as a webcast on

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to

SOURCE: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193

ShareThis Copy and Paste